Fidelis Capital Partners LLC Sells 108 Shares of Cencora, Inc. (NYSE:COR)

Fidelis Capital Partners LLC reduced its position in shares of Cencora, Inc. (NYSE:COR) by 7.2% in the second quarter, according to its most recent filing with the SEC. The fund owned 1,394 shares of the company’s stock after selling 108 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Cencora were worth $336,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. bought a new position in Cencora during the fourth quarter valued at $4,212,508,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Cencora during the 1st quarter valued at about $2,183,619,000. JPMorgan Chase & Co. purchased a new stake in shares of Cencora during the 1st quarter valued at about $1,199,695,000. Boston Partners bought a new position in shares of Cencora in the 1st quarter valued at about $1,001,269,000. Finally, Capital Research Global Investors purchased a new position in Cencora in the first quarter worth about $650,424,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Up 0.1 %

NYSE:COR opened at $228.36 on Tuesday. The company has a market cap of $45.55 billion, a price-to-earnings ratio of 24.98, a price-to-earnings-growth ratio of 1.55 and a beta of 0.44. Cencora, Inc. has a twelve month low of $178.21 and a twelve month high of $247.66. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93. The stock has a fifty day simple moving average of $234.97 and a 200-day simple moving average of $233.04.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.18 by $0.16. The company had revenue of $74.20 billion during the quarter, compared to analysts’ expectations of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The firm’s quarterly revenue was up 10.8% on a year-over-year basis. During the same period in the previous year, the company earned $2.92 EPS. Analysts anticipate that Cencora, Inc. will post 13.63 EPS for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were paid a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date was Friday, August 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Insider Transactions at Cencora

In related news, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the transaction, the executive vice president now owns 10,948 shares of the company’s stock, valued at $2,656,970.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Steven H. Collis sold 10,755 shares of the firm’s stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the sale, the chief executive officer now owns 285,088 shares of the company’s stock, valued at $63,323,746.56. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the transaction, the executive vice president now owns 10,948 shares of the company’s stock, valued at $2,656,970.12. The disclosure for this sale can be found here. In the last quarter, insiders sold 4,450,399 shares of company stock valued at $1,070,392,799. Company insiders own 15.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday. Wells Fargo & Company increased their price target on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. Leerink Partners reaffirmed an “outperform” rating and set a $275.00 price objective on shares of Cencora in a research note on Thursday, June 27th. Robert W. Baird reduced their target price on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research note on Friday, September 6th. Finally, Bank of America restated a “neutral” rating and issued a $245.00 target price (down previously from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.67.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.